Paxlovid tied to fewer COVID-19 hospitalizations, reduced risk of long COVID --study
Submitted by mike kraft on

A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.